The Pharma Data

MAY 8, 2021

The global development program for Sandoz’ biosimilar aflibercept was developed in consultation with major regulatory agencies and the results from this clinical study are expected to support regulatory submissions. Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. Disclaimer. About Sandoz.

Clinical Development 52

Clinical Development Medicine Development Containment 52

The Pharma Data

MAY 18, 2021

Sandoz is the global leader in generic antibiotics and operates the only vertically-integrated antibiotic network left in Europe, despite fierce competition from Asia. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

Manufacturing 40

Manufacturing Production Containment Generic Pharmaceutical 40

The Pharma Data

MAY 2, 2021

The global development program for Sandoz’ biosimilar aflibercept was developed in consultation with major regulatory agencies and the results from this clinical study are expected to support regulatory submissions. Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. Disclaimer. About Sandoz.

Clinical Development 40

Clinical Development Medicine Development Production 40

The Pharma Data

MAY 15, 2023

For more information on the Sandoz Board of Directors, please also see [link] Disclaimer This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Our ambition is to be the world’s leading and most valued generics company.

Sales 40

Sales Production Doctors Doctor 40

XTalks

AUGUST 2, 2023

It contains the antiviral medications nirmatrelvir and ritonavir. It works by containing lymphocytes within the lymph nodes , preventing them from entering the central nervous system via the blood-brain barrier and causing an autoimmune reaction that destroys myelin on neurons. In 2022, Biktarvy generated $10.39 billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

DECEMBER 23, 2020

24, 2020 /PRNewswire/ — COVAXX’s UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate. .

Vaccination 52

Vaccination Vaccine Development Manufacturing 52

The Pharma Data

DECEMBER 23, 2020

This vaccine has immense potential in eliminating shedding and hence containing the spread of the pandemic.”. COVAXX is currently completing a Phase 1 clinical trial of UB-612 in Taiwan and will begin Phase 2/3 clinical trials in Asia, Latin America and the U.S. UB-612 Fact Sheet: www.covaxx.com/vaccine.

Vaccination 52

Vaccination Vaccine Manufacturing Antibody 52